Liraglutide Research for Type 2 Diabetes
An evidence-based overview of research examining Liraglutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Victoza is FDA-approved for glycemic control in type 2 diabetes from age 10 years. In the cited two-year LEAD-3 follow-up, HbA1c fell by 0.6 and 0.9 percentage points with the two liraglutide groups versus 0.3 points with glimepiride. LEAD-6 found a larger HbA1c reduction than its tested twice-daily exenatide comparator. LEADER (N=9,340) found a 13% relative reduction in major adverse cardiovascular events in its high-risk T2D population; it is a different endpoint and cohort.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.